14 completed, 7 terminated, 5 unknown, 4 recruiting. 13 Phase 2, 13 Phase 3, 4 Phase 1, 1 Not applicable, 1 Phase 4.
Follow Alfasigma S.p.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents Filgotinib - Polyarticular Course Juvenile Idiopathic Arthritis | Phase 3 | Recruiting | Alfasigma S.p.A. | 65 | 2026-05-21 | 2026-06-12 |
| OLE Study With Filgotinib in JIA Filgotinib - Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2026-04-20 | 2026-08-10 |
| A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis Filgotinib - Ulcerative Colitis | Phase 3 | Recruiting | Alfasigma S.p.A. | 80 | 2025-09-29 | 2026-10-20 |
| Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) Filgotinib - Juvenile Idiopathic Arthritis | Phase 1 | Terminated | Alfasigma S.p.A. | 9 | 2024-05-13 | 2026-07-15 |
| Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | UMC Utrecht | 60 | 2024-03-12 | 2026-05-12 |
| Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study Rheumatoid Arthritis, Atherosclerotic Ischemic Disease | Enrolling by invitation | Ellen Margrethe Hauge | 4000 | 2024-02-21 | 2026-02-03 | |
| Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) Filgotinib - Ulcerative Colitis | Active not recruiting | Alfasigma S.p.A. | 509 | 2023-06-12 | 2025-12-24 | |
| Endothelial Protection in Post COVID-19 Patients With Sulodexide Sulodexide - Post COVID-19, Endothelial Dysfunction | Phase 3 | Completed | Centro Medico del Noroeste | 206 | 2023-06-01 | 2024-08-09 |
| A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis Filgotinib, Placebo - Axial Spondyloarthritis | Phase 3 | Active not recruiting | Alfasigma S.p.A. | 495 | 2023-04-05 | 2025-12-04 |
| Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France Filgotinib - Rheumatoid Arthritis | Completed | Alfasigma S.p.A. | 155 | 2022-05-03 | 2026-05-22 | |
| Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). Velusetrag 15 mg once daily for 4 weeks., Placebo once daily for 4 weeks. - Chronic Intestinal Pseudo-obstruction | Phase 2 | Completed | Alfasigma S.p.A. | 17 | 2021-12-15 | 2025-08-03 |
| Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities Vessel, Placebo - Chronic Venous Disease, Chronic Insufficiency Venous | Phase 3 | Unknown | Value Outcomes Ltd. | 290 | 2021-11-25 | 2023-06-22 |
| Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea Rifaximin, Placebo - Papulopustular Rosacea | Phase 2 | Completed | Alfasigma S.p.A. | 216 | 2021-10-05 | 2024-04-24 |
| Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis Filgotinib - Rheumatoid Arthritis | Active not recruiting | Alfasigma S.p.A. | 1304 | 2021-05-11 | 2025-09-15 | |
| Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis 2-liters polyethylene glycol with citrate and simethicone, 4-liters polyethylene glycol with simethicone, Low-residue diet - Chronic Kidney Diseases, Colon Polyp | Phase 4 | Unknown | Alfredo Di Leo | 264 | 2021-02-01 | 2021-01-14 |
| Suloexide in the Treatment of Early Stages of COVID-19 Sulodexide, Placebo - Covid19 | Phase 2 / Phase 3 | Completed | Clinedem | 243 | 2020-06-05 | 2020-09-09 |
| STUDY OF THE EFFECTS OF L. CASEI DG® (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS. Enterolactis Baby® drops, Placebo - Gut Microbiota Modulation | Not applicable | Completed | Alfasigma S.p.A. | 61 | 2018-11-02 | 2026-10-20 |
| Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. Rifaximin delayed released 400mg Tablet, Placebo - Diverticulitis | Phase 2 / Phase 3 | Terminated | Alfasigma S.p.A. | 193 | 2018-07-02 | 2021-10-20 |
| Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test Rifaximin delayed release 400 mg tablet, Placebo - Papulopustular Rosacea | Phase 2 | Unknown | Alfasigma S.p.A. | 236 | 2018-06-22 | 2019-03-11 |
| Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites Rifaximin, Placebo - Cirrhosis, Ascites | Phase 3 | Completed | Centre Hospitalier Universitaire de Besancon | 160 | 2018-06-05 | 2025-04-10 |
Showing 20 of 34. Sign in to see all of them.
Arthritis, Rheumatoid (4) · Arthritis, Juvenile (3) · Colitis, Ulcerative (3) · Crohn Disease (2) · Gastroparesis (2) · Renal Insufficiency, Chronic (2) · Rosacea (2) · Alzheimer Disease (1) · Anxiety Disorders (1) · Ascites (1) · Axial Spondyloarthritis (1) · Behcet Syndrome (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Cardiovascular Diseases (1)
GLPG0634 (11) · TD-5108 (5) · glucuronyl glucosamine glycan sulfate (3) · Rifaximin (2) · Tablets (2) · Benchmarking (1) · Citric Acid (1) · Glycosaminoglycans (1) · Simethicone (1) · artenimol (1) · klean prep (1) · piperaquine (1)
Italy (16) · France (14) · Germany (12) · Spain (11) · United Kingdom (10) · Belgium (9) · United States (8) · Netherlands (7) · Poland (7) · Czechia (5) · Hungary (5) · Ireland (4) · Israel (4) · Mexico (4) · Romania (4)
Maria Grimaldi, MD (2) · Alejandro J Gonzalez-Ochoa, MD (1) · Alexander Haug, MD (1) · Alexandra Heurgue-Berlot, MD (1) · Alexandre Louvet, MD, PhD (1) · Alfredo Di Leo, MD PhD (1) · Andreas Wicki, MD (1) · Catherine Vincent (1) · Christoph Hatz, Prof Dr Med (1) · Christophe Bureau, MD, PhD (1) · Claire Francoz, MD (1) · Cosimo Prantera, MD (1)
PMID 30867794, PMID 42536126, PMID 21039672, PMID 22155172, PMID 26167947, PMID 26575422, PMID 27487795, PMID 27603372, PMID 28186982, PMID 33811761, PMID 35244208, PMID 36205910, PMID 36624727, PMID 37540206, PMID 37718932, PMID 37747626, PMID 39086130, PMID 39506562, PMID 39915014, PMID 40653111, PMID 41039829, PMID 41553253, PMID 41841789
2016 (2), 2017 (2), 2023 (1), 2025 (1)